CRISPR Therapeutics AG Stock Analysis & AI Score
CRISPR Therapeutics AG (CRSP) has an ST Score of 62.7 (B), driven by its Sentiment (A+) and held back by its Forecast (B-). Analysts rate it Buy with a $67.83 price target (+21.8% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
CRISPR Therapeutics AG (CRSP) has an ST Score of 62.7 (B), driven by its Sentiment (A+) and held back by its Forecast (B-). Analysts rate it Buy with a $67.83 price target (+21.8% upside).
- Strongest
- SentimentA+
- Weakest
- ForecastB-
All factor grades
- SentimentA+
- ProfitabilityA-
- MomentumB+
- ValuationB
- Financial StrengthB
- GrowthB-
- ForecastB-
- Piotroski2/9
Contact
CRSP stock: frequently asked questions
What is CRSP's ST Score?
CRISPR Therapeutics AG (CRSP) has an ST Score of 62.7 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CRSP a buy, hold, or sell?
Analysts rate CRSP a Buy, with a price target of $67.83 (+21.8% vs the current price). Our ST Score grades it B (62.7/100). The ST Score is a data-driven signal, not a recommendation.
What are CRSP's factor grades?
Valuation B, Profitability A-, Financial Strength B, Momentum B+, Growth B-, Forecast B-, Sentiment A+.
What is CRSP's valuation grade?
CRISPR Therapeutics AG (CRSP) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CRSP's growth grade?
CRISPR Therapeutics AG (CRSP) earns a growth grade of B-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CRSP's profitability grade?
CRISPR Therapeutics AG (CRSP) earns a profitability grade of A-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CRSP's financial strength grade?
CRISPR Therapeutics AG (CRSP) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CRSP?
The average analyst price target for CRISPR Therapeutics AG (CRSP) is $67.83 from 38 analysts, which is +21.8% versus the recent price of $55.70.
What is CRSP's Piotroski score?
CRISPR Therapeutics AG (CRSP) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.